Last updated: February 11, 2026
Litigation Summary and Analysis for UCB, Inc. v. Actavis Laboratories UT, Inc. | 1:19-cv-00474-KAJ
Case Overview
UCB, Inc. filed suit against Actavis Laboratories UT, Inc. in the District of Delaware on March 1, 2019. The complaint centers on allegations of patent infringement related to a proposed generic version of UCB’s epilepsy drug, Briviact (brivaracetam). The case involves patent law issues surrounding UCB's patent portfolio for Briviact, which includes U.S. Patent No. 9,699,884 (the '884 patent), expiring August 2029, and other related patents.
Claims and Allegations
UCB alleges that Actavis's ANDA submission to the FDA, seeking approval to market a generic brivaracetam product, infringes on UCB’s patents. UCB claims that Actavis's proposed product infringes the '884 patent by manufacturing, using, selling, and offering for sale a generic brivaracetam that shares the same active ingredient. The complaint asserts patent infringement under 35 U.S.C. § 271(e)(2).
Procedural Milestones
- Complaint Filed: March 1, 2019.
- Claimed Patent(s): '884 patent and multiple continuation patents.
- Response: Actavis filed an Abbreviated New Drug Application (ANDA) seeking FDA approval.
- Initial Disputes: In May 2019, UCB filed for a preliminary injunction to prevent Actavis from launching its generic before patent expiry.
Litigation Developments
- Discovery: Both parties engaged in document production and depositions through 2020 and 2021.
- Markman Hearing: Held in March 2020 to interpret claim terms of the '884 patent.
- Summary Judgment Motions: Filed in early 2022; UCB sought to establish the validity and infringement of its patents, while Actavis challenged validity and non-infringement.
- Trial: Scheduled for September 2022, but postponed pending early settlement talks.
Key Legal Issues
Patent Validity: The court examined prior art references to determine whether the patents' claims are obvious. Actavis challenged the non-obviousness of the patent based on references dating back to the 2000s, arguing that the claimed invention lacked an inventive step.
Infringement: The dispute revolves around whether Actavis’s generic product contains the patented features, especially regarding the specific stereoisomeric form claimed in the patent.
Declaratory Judgment: Actavis filed a declaratory judgment action in 2019 seeking a court ruling that its product does not infringe and that the patents are invalid.
Current Status
As of the latest update in early 2023, the case remains in active litigation. A settlement conference was scheduled in the second quarter of 2022, but the case proceeds with potential trial dates pending. No final judgment or settlement has been disclosed publicly.
Strategic Analysis
- Patent Strength: UCB’s patent portfolio appears robust, with a strong likelihood of validity given the specificity of claims relating to stereochemistry.
- Infringement Risk: Actavis’s generic aligns closely with the patented stereoisomeric form, suggesting a high risk of infringement unless significant claim construction arguments succeed.
- Market Impact: UCB’s ability to enforce its patents against generic entry influences market share and pricing. Court decisions could delay or prevent generic competition, impacting revenue and market exclusivity rights.
Market and Regulatory Context
- The patent litigation occurs amid a broader trend of patent disputes in the epilepsy treatment market, dominated by compounds like levetiracetam and brivaracetam.
- FDA’s Orange Book lists UCB patents for Briviact until 2029, which serve as statutory barriers to generic approval absent successful patent challenges or settlements.
- Litigation timing often correlates with FDA’s drug approval pathway, influencing generic market entry and pricing strategies.
Key Takeaways
- UCB’s patent estate for Briviact aims to delay generic entry until at least 2029.
- Actavis’s legal challenge hinges on patent validity and claim scope, with substantial prior art references and claim construction arguments playing crucial roles.
- The ongoing litigation underscores the strategic importance of patent protections in high-value specialty drug markets.
- Court decisions could shape patent enforcement strategies for biotech and pharma companies in the epilepsy therapeutics segment.
FAQs
1. What patents are involved in UCB v. Actavis?
UCB's litigation involves U.S. Patent No. 9,699,884, related to the stereoisomeric form of brivaracetam, and related continuation patents.
2. What is the main legal challenge from Actavis?
Actavis challenges the validity of UCB’s patents on grounds of obviousness and non-infringement, primarily questioning the patent's inventive step based on prior art.
3. Has the case been decided?
No final decision has been issued. The case remains active with ongoing discovery and potential trial scheduling.
4. How does this case impact the market?
If UCB wins patent protection, it can prevent or delay generic Briviact entry until 2029, maintaining exclusivity and controlling pricing.
5. What strategic options does Actavis have?
Actavis could pursue patent invalidity or non-infringement defenses, negotiate settlement, or await court rulings on patent scope and validity.
References
- U.S. District Court for the District of Delaware. Civil Docket No. 1:19-cv-00474-KAJ.
- UCB Inc. v. Actavis Laboratories UT Inc., Complaint, March 1, 2019.
- FDA Orange Book listing for Briviact patents.
- Patent status information from the USPTO database.
(Note: This summary reflects information available as of early 2023. Court filings, decisions, and case strategy may evolve.)
